Answers are grounded in this paper and cite their sources.
Alport Syndrome (AS), particularly autosomal dominant AS, can range in severity from microscopic hematuria to end-stage kidney disease (ESKD), and often goes undiagnosed. With increased availability of genetic testing and recognition of the importance of AS in chronic kidney disease (CKD), there is a need to understand the molecular diagnostic yield across various phenotypes and settings. We hypothesized that the molecular diagnostic yield would be lower in largely unselected health system cohorts compared to a multidisciplinary renal genetics cohort.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: